Integrated transcriptome analysis of human iPS cells derived from a fragile X syndrome patient during neuronal differentiation

Science China Life Sciences

Volumn 59, Issue 11, 2016, Pages 1093-1105

  Lu, Ping ^a   Chen, Xiaolong ^b   Feng, Yun ^a   Zeng, Qiao ^a   Jiang, Cizhong ^b   Zhu, Xianmin ^b   Fan, Guoping ^b,c   Xue, Zhigang ^a,b  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b TONGJI UNIVERSITY   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

fragile X syndrome; induced pluripotent stem cells; neuronal differentiation; transcriptome

Indexed keywords

FMR1 PROTEIN, HUMAN; FRAGILE X MENTAL RETARDATION PROTEIN;

ANIMAL; CELL CULTURE; CELL DIFFERENTIATION; CELL LINE; CLUSTER ANALYSIS; FLUORESCENCE MICROSCOPY; FRAGILE X SYNDROME; GENE EXPRESSION PROFILING; GENE ONTOLOGY; GENE REGULATORY NETWORK; GENETICS; HUMAN; INDUCED PLURIPOTENT STEM CELL; METABOLISM; MOUSE; NERVE CELL; NERVOUS SYSTEM DEVELOPMENT; PATHOLOGY; PROCEDURES; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS;

ANIMALS; CELL DIFFERENTIATION; CELL LINE; CELLS, CULTURED; CLUSTER ANALYSIS; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; GENE EXPRESSION PROFILING; GENE ONTOLOGY; GENE REGULATORY NETWORKS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MICE; MICROSCOPY, FLUORESCENCE; NEUROGENESIS; NEURONS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, RNA;

EID: 84991109567     PISSN: 16747305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11427-016-0194-6     Document Type: Article

References (71)

1. Alpatov, R., Lesch, B.J., Nakamoto-Kinoshita, M., Blanco, A., Chen, S., Stützer, A., Armache, K.J., Simon, M.D., Xu, C., Ali, M., Murn, J., Prisic, S., Kutateladze, T.G., Vakoc, C.R., Min, J., Kingston, R.E., Fischle, W., Warren, S.T., Page, D.C., and Shi, Y. (2014). A chromatin- dependent role of the fragile X mental retardation protein FMRP in the DNA damage response. Cell 157, 869–881.
2. Ascano, M., Mukherjee, N., Bandaru, P., Miller, J.B., Nusbaum, J.D., Corcoran, D.L., Langlois, C., Munschauer, M., Dewell, S., Hafner, M., Williams, Z., Ohler, U., and Tuschl, T. (2012). FMRP targets distinct mRNA sequence elements to regulate protein expression. Nature 492, 382–386.
3. Auerbach, B.D., Osterweil, E.K., and Bear, M.F. (2011). Mutations causing syndromic autism define an axis of synaptic pathophysiology. Nature 480, 63–68.
4. Bagni, C., Tassone, F., Neri, G., and Hagerman, R. (2012). Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics. J Clin Invest 122, 4314–4322.
5. Bear, M.F., Huber, K.M., and Warren, S.T. (2004). The mGluR theory of fragile X mental retardation. Trends Neurosci 27, 370–377.
6. Bittel, D.C., Kibiryeva, N., and Butler, M.G. (2007). Whole genome microarray analysis of gene expression in subjects with fragile X syndrome. Genet Med 9, 464–472.
7. Brick, D.J., Nethercott, H.E., Montesano, S., Banuelos, M.G., Stover, A.E., Schutte, S.S., O’Dowd, D.K., Hagerman, R.J., Ono, M., Hessl, D.R., Tassone, F., and Schwartz, P.H. (2014). The autism spectrum disorders stem cell resource at children’s hospital of orange county: implications for disease modeling and drug discovery. Stem Cells Transl Med 3, 1275–1286.
8. Brown, M.R., Kronengold, J., Gazula, V.R., Chen, Y., Strumbos, J.G., Sigworth, F.J., Navaratnam, D., and Kaczmarek, L.K. (2010). Fragile X mental retardation protein controls gating of the sodium-activated potassium channel Slack. Nat Neurosci 13, 819–821.
9. Cruz-Martin, A., Crespo, M., and Portera-Cailliau, C. (2010). Delayed stabilization of dendritic spines in fragile X mice. J Neurosci 30, 7793–7803.
10. D’Agata, V., Warren, S.T., Zhao, W., Torre, E.R., Alkon, D.L., and Cavallaro, S. (2002). Gene expression profiles in a transgenic animal model of fragile X syndrome. Neurobiol Dis 10, 211–218.
11. D’Hulst, C., and Kooy, R.F. (2007). The GABAA receptor: a novel target for treatment of fragile X? Trends Neurosci 30, 425–431.
12. Darnell, J.C., and Klann, E. (2013). The translation of translational control by FMRP: therapeutic targets for FXS. Nat Neurosci 16, 1530–1536.
13. Darnell, J.C., Van Driesche, S.J., Zhang, C., Hung, K.Y.S., Mele, A., Fraser, C.E., Stone, E.F., Chen, C., Fak, J.J., Chi, S.W., Licatalosi, D.D., Richter, J.D., and Darnell, R.B. (2011). FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 146, 247–261.
14. Deng, P.Y., Rotman, Z., Blundon, J.A., Cho, Y., Cui, J., Cavalli, V., Zakharenko, S.S., and Klyachko, V.A. (2013). FMRP regulates neurotransmitter release and synaptic information transmission by modulating action potential duration via BK channels. Neuron 77, 696–711.
15. Devitt, N., Gallagher, L., and Reilly, R. (2015). Autism Spectrum Disorder (ASD) and Fragile X Syndrome (FXS): two overlapping disorders reviewed through electroencephalography—what can be interpreted from the available information? Brain Scis 5, 92–117.
16. Devys, D., Lutz, Y., Rouyer, N., Bellocq, J.P., and Mandel, J.L. (1993). The FMR-1 protein is cytoplasmic, most abundant in neurons and appears normal in carriers of a fragile X premutation. Nat Genet 4, 335–340.
17. Dolen, G., Osterweil, E., Rao, B.S., Smith, G.B., Auerbach, B.D., Chattarji, S., and Bear, M.F. (2007). Correction of fragile X syndrome in mice. Neuron 56, 955–962.
18. Eberhart, D.E., Malter, H.E., Feng, Y., and Warren, S.T. (1996). The fragile X mental retardation protein is a ribonucleoprotein containing both nuclear localization and nuclear export signals. Hum Mol Genet 5, 1083–1091.
19. Eiges, R., Urbach, A., Malcov, M., Frumkin, T., Schwartz, T., Amit, A., Yaron, Y., Eden, A., Yanuka, O., Benvenisty, N., and Ben-Yosef, D. (2007). Developmental study of fragile X syndrome using human embryonic stem cells derived from preimplantation genetically diagnosed embryos. Cell Stem Cell 1, 568–577.
20. Feng, Y., Gutekunst, C.A., Eberhart, D.E., Yi, H., Warren, S.T., and Hersch, S.M. (1997). Fragile X mental retardation protein: nucleocytoplasmic shuttling and association with somatodendritic ribosomes. J Neurosci 17, 1539–1547.
21. Goebel-Goody, S.M., Wilson-Wallis, E.D., Royston, S., Tagliatela, S.M., Naegele, J.R., and Lombroso, P.J. (2012). Genetic manipulation of STEP reverses behavioral abnormalities in a fragile X syndrome mouse model. Genes Brain Behav 11, 586–600.
22. Halevy, T., Czech, C., and Benvenisty, N. (2015). Molecular mechanisms regulating the defects in fragile X syndrome neurons derived from human pluripotent stem cells. Stem Cell Rep 4, 37–46.
23. Hayashi, M.L., Shankaranarayana Rao, B.S., Seo, J.S., Choi, H.S., Dolan, B.M., Choi, S.Y., Chattarji, S., and Tonegawa, S. (2007). Inhibition of p21-activated kinase rescues symptoms of fragile X syndrome in mice. Proc Natl Acad Sci USA 104, 11489–11494.
24. Huang da, W., Sherman, B.T., and Lempicki, R.A. (2009). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4, 44–57.
25. Huang, S., and Fu, X.B. (2014). Stem cell therapies and regenerative medicine in China. Sci China Life Sci 57, 157–161.
26. Hung, A.Y., Futai, K., Sala, C., Valtschanoff, J.G., Ryu, J., Woodworth, M.A., Kidd, F.L., Sung, C.C., Miyakawa, T., Bear, M.F., Weinberg, R.J., and Sheng, M. (2008). Smaller dendritic spines, weaker synaptic transmission, but enhanced spatial learning in mice lacking Shank1. J Neurosci 28, 1697–1708.
27. Johnson, M.B., Kawasawa, Y.I., Mason, C.E., Krsnik-Coppola, G., Bogdanović, D., Geschwind, D.H., Mane, S.M., State, M.W., and Šestan, N. (2009). Functional and evolutionary insights into human brain development through global transcriptome analysis. Neuron 62, 494–509.
28. Joseph, R., Tsang, W., Dou, D., Nelson, K., and Edvardsen, K. (1996). Neuronatin mRNA in PC12 cells: downregulation by nerve growth factor. Brain Res 738, 32–38.
29. Kang, H.J., Kawasawa, Y.I., Cheng, F., Zhu, Y., Xu, X., Li, M., Sousa, A.M.M., Pletikos, M., Meyer, K.A., Sedmak, G., Guennel, T., Shin, Y., Johnson, M.B., Krsnik, Z., Mayer, S., Fertuzinhos, S., Umlauf, S., Lisgo, S.N., Vortmeyer, A., Weinberger, D.R., Mane, S., Hyde, T.M., Huttner, A., Reimers, M., Kleinman, J.E., and Sestan, N. (2011). Spatio-temporal transcriptome of the human brain. Nature 478, 483–489.
30. Kao, D.I., Aldridge, G.M., Weiler, I.J., and Greenough, W.T. (2010). Altered mRNA transport, docking, and protein translation in neurons lacking fragile X mental retardation protein. Proc Natl Acad Sci USA 107, 15601–15606.
31. Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., and Salzberg, S.L. (2013). TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol 14, R36.
32. Laggerbauer, B., Ostareck, D., Keidel, E.M., Ostareck-Lederer, A., and Fischer, U. (2001). Evidence that fragile X mental retardation protein is a negative regulator of translation. Hum Mol Genet 10, 329–338.
33. Leblond, C.S., Nava, C., Polge, A., Gauthier, J., Huguet, G., Lumbroso, S., Giuliano, F., Stordeur, C., Depienne, C., Mouzat, K., Pinto, D., Howe, J., Lemière, N., Durand, C.M., Guibert, J., Ey, E., Toro, R., Peyre, H., Mathieu, A., Amsellem, F., Rastam, M., Gillberg, I.C., Rappold, G.A., Holt, R., Monaco, A.P., Maestrini, E., Galan, P., Heron, D., Jacquette, A., Afenjar, A., Rastetter, A., Brice, A., Devillard, F., Assouline, B., Laffargue, F., Lespinasse, J., Chiesa, J., Rivier, F., Bonneau, D., Regnault, B., Zelenika, D., Delepine, M., Lathrop, M., Sanlaville, D., Schluth-Bolard, C., Edery, P., Perrin, L., Tabet, A.C., Schmeisser, M.J., Boeckers, T.M., Coleman, M., Sato, D., Szatmari, P., Scherer, S.W., Rouleau, G.A., Betancur, C., Leboyer, M., Gillberg, C., Delorme, R., Bourgeron, T., and Barsh, G.S. (2014). Meta-analysis of SHANK mutations in autism spectrum disorders: a gradient of severity in cognitive impairments. PLoS Genet 10, e1004580.
34. Lee, H.Y., Ge, W.P., Huang, W., He, Y., Wang, G.X., Rowson-Baldwin, A., Smith, S.J., Jan, Y.N., and Jan, L.Y. (2011). Bidirectional regulation of dendritic voltage-gated potassium channels by the fragile X mental retardation protein. Neuron 72, 630–642.
35. Lee, H.Y., and Jan, L.Y. (2012). Fragile X syndrome: mechanistic insights and therapeutic avenues regarding the role of potassium channels. Curr Opin Neurobiol 22, 887–894.
36. Li, W., and Cornell, R.A. (2007). Redundant activities of Tfap2a and Tfap2c are required for neural crest induction and development of other non-neural ectoderm derivatives in zebrafish embryos. Dev Biol 304, 338–354.
37. Liao, J.L., Yu, J., Huang, K., Hu, J., Diemer, T., Ma, Z., Dvash, T., Yang, X.J., Travis, G.H., Williams, D.S., Bok, D., and Fan, G. (2010). Molecular signature of primary retinal pigment epithelium and stem-cell-derived RPE cells. Human Mol Genets 19, 4229–4238.
38. Lindemann, L., Jaeschke, G., Michalon, A., Vieira, E., Honer, M., Spooren, W., Porter, R., Hartung, T., Kolczewski, S., Buttelmann, B., Flament, C., Diener, C., Fischer, C., Gatti, S., Prinssen, E.P., Parrott, N., Hoffmann, G., and Wettstein, J.G. (2011). CTEP: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor. J Pharmacol Exp Ther 339, 474–486.
39. Lu, R., Wang, H., Liang, Z., Ku, L., O’Donnell, W.T., Li, W., Warren, S.T., and Feng, Y. (2004). The fragile X protein controls microtubule-associated protein 1B translation and microtubule stability in brain neuron development. Proc Natl Acad Sci USA 101, 15201–15206.
40. Michalon, A., Sidorov, M., Ballard, T.M., Ozmen, L., Spooren, W., Wettstein, J.G., Jaeschke, G., Bear, M.F., and Lindemann, L. (2012). Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron 74, 49–56.
41. Mohrenweiser, H.W., Tsujimoto, S., Gordon, L., and Olsen, A.S. (1998). Regions of sex-specific hypo- and hyper-recombination identified through integration of 180 genetic markers into the metric physical map of human chromosome 19. Genomics 47, 153–162.
42. Monsoro-Burq, A.H. (2015). PAX transcription factors in neural crest development. Semin Cell Dev Biol 44, 87–96.
43. Muddashetty, R.S., Kelic, S., Gross, C., Xu, M., and Bassell, G.J. (2007). Dysregulated metabotropic glutamate receptor-dependent translation of AMPA receptor and postsynaptic density-95 mRNAs at synapses in a mouse model of fragile X syndrome. J Neurosci 27, 5338–5348.
44. Nelson, D.L., Orr, H.T., and Warren, S.T. (2013). The unstable repeats— three evolving faces of neurological disease. Neuron 77, 825–843.
45. Ninkovic, J., Steiner-Mezzadri, A., Jawerka, M., Akinci, U., Masserdotti, G., Petricca, S., Fischer, J., von Holst, A., Beckers, J., Lie, C.D., Petrik, D., Miller, E., Tang, J., Wu, J., Lefebvre, V., Demmers, J., Eisch, A., Metzger, D., Crabtree, G., Irmler, M., Poot, R., and Götz, M. (2013). The BAF complex interacts with Pax6 in adult neural progenitors to establish a neurogenic cross-regulatory transcriptional network. Cell Stem Cell 13, 403–418.
46. Osterweil, E.K., Krueger, D.D., Reinhold, K., and Bear, M.F. (2010). Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome. J Neurosci 30, 15616–15627.
47. Pan, F., Aldridge, G.M., Greenough, W.T., and Gan, W.B. (2010). Dendritic spine instability and insensitivity to modulation by sensory experience in a mouse model of fragile X syndrome. Proc Natl Acad Sci USA 107, 17768–17773.
48. Pasca, S.P., Portmann, T., Voineagu, I., Yazawa, M., Shcheglovitov, A., Pasca, A.M., Cord, B., Palmer, T.D., Chikahisa, S., Nishino, S., Bernstein, J.A., Hallmayer, J., Geschwind, D.H., and Dolmetsch, R.E. (2011). Using iPSC-derived neurons to uncover cellular phenotypes associated with Timothy syndrome. Nat Med 17, 1657–1662.
49. Pfeiffer, B.E., and Huber, K.M. (2007). Fragile X mental retardation protein induces synapse loss through acute postsynaptic translational regulation. J Neurosci 27, 3120–3130.
50. Pletikos, M., Sousa, A.M.M., Sedmak, G., Meyer, K.A., Zhu, Y., Cheng, F., Li, M., Kawasawa, Y.I., and Šestan, N. (2014). Temporal specification and bilaterality of human neocortical topographic gene expression. Neuron 81, 321–332.
51. Qin, M., Kang, J., Burlin, T.V., Jiang, C., and Smith, C.B. (2005). Postadolescent changes in regional cerebral protein synthesis: an in vivo study in the FMR1 null mouse. J Neurosci 25, 5087–5095.
52. Sato, D., Lionel, A.C., Leblond, C.S., Prasad, A., Pinto, D., Walker, S., O’Connor, I., Russell, C., Drmic, I.E., Hamdan, F.F., Michaud, J.L., Endris, V., Roeth, R., Delorme, R., Huguet, G., Leboyer, M., Rastam, M., Gillberg, C., Lathrop, M., Stavropoulos, D.J., Anagnostou, E., Weksberg, R., Fombonne, E., Zwaigenbaum, L., Fernandez, B.A., Roberts, W., Rappold, G.A., Marshall, C.R., Bourgeron, T., Szatmari, P., and Scherer, S.W. (2012). SHANK1 deletions in males with autism spectrum disorder. Am J Human Genets 90, 879–887.
53. Schutt, J., Falley, K., Richter, D., Kreienkamp, H.J., and Kindler, S. (2009). Fragile X mental retardation protein regulates the levels of scaffold proteins and glutamate receptors in postsynaptic densities. J Biol Chem 284, 25479–25487.
54. Sharma, A., Hoeffer, C.A., Takayasu, Y., Miyawaki, T., McBride, S.M., Klann, E., and Zukin, R.S. (2010). Dysregulation of mTOR signaling in fragile X syndrome. J Neurosci 30, 694–702.
55. Sharma, J., Mukherjee, D., Rao, S.N.R., Iyengar, S., Shankar, S.K., Satishchandra, P., and Jana, N.R. (2013). Neuronatin-mediated aberrant calcium signaling and endoplasmic reticulum stress underlie neuropathology in lafora disease. J Biol Chem 288, 9482–9490.
56. Sharma, J., Rao, S.N.R., Shankar, S.K., Satishchandra, P., and Jana, N.R. (2011). Lafora disease ubiquitin ligase malin promotes proteasomal degradation of neuronatin and regulates glycogen synthesis. Neurobiol Dis 44, 133–141.
57. Sheridan, S.D., Theriault, K.M., Reis, S.A., Zhou, F., Madison, J.M., Daheron, L., Loring, J.F., Haggarty, S.J., and Cookson, M.R. (2011). Epigenetic characterization of the FMR1 gene and aberrant neurodevelopment in human induced pluripotent stem cell models of fragile X syndrome. PLoS ONE 6, e26203.
58. Sittler, A., Devys, D., Weber, C., and Mandel, J.L. (1996). Alternative splicing of exon 14 determines nuclear or cytoplasmic localisation of FMR1 protein isoforms. Human Mol Genets 5, 95–102.
59. Strumbos, J.G., Brown, M.R., Kronengold, J., Polley, D.B., and Kaczmarek, L.K. (2010). Fragile X mental retardation protein is required for rapid experience- dependent regulation of the potassium channel Kv3.1b. J Neurosci 30, 10263–10271.
60. Surendran, S., Tyring, S.K., and Matalon, R. (2005). Expression of calpastatin, minopontin, NIPSNAP1, rabaptin-5 and neuronatin in the phenylketonuria (PKU) mouse brain: possible role on cognitive defect seen in PKU. Neurochem Int 46, 595–599.
61. Tapper, W., Collins, A., Gibson, J., Maniatis, N., Ennis, S., and Morton, N.E. (2005). A map of the human genome in linkage disequilibrium units. Proc Natl Acad Sci USA 102, 11835–11839.
62. Telias, M., Segal, M., and Ben-Yosef, D. (2013). Neural differentiation of fragile X human embryonic stem cells reveals abnormal patterns of development despite successful neurogenesis. Dev Biol 374, 32–45.
63. The Dutch-Belgian Fragile X Consorthium, C.E.B., and Coleta Verheij, Rob Willemsen. (Willems 1994). Fmr1 knockout mice: a model to study fragile X mental retardation. Cell 78, 23–33.
64. Trapnell, C., Roberts, A., Goff, L., Pertea, G., Kim, D., Kelley, D.R., Pimentel, H., Salzberg, S.L., Rinn, J.L., and Pachter, L. (2012). Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc 7, 562–578.
65. Vaquerizas, J.M., Kummerfeld, S.K., Teichmann, S.A., and Luscombe, N.M. (2009). A census of human transcription factors: function, expression and evolution. Nat Rev Genet 10, 252–263.
66. Warde-Farley, D., Donaldson, S.L., Comes, O., Zuberi, K., Badrawi, R., Chao, P., Franz, M., Grouios, C., Kazi, F., Lopes, C.T., Maitland, A., Mostafavi, S., Montojo, J., Shao, Q., Wright, G., Bader, G.D., and Morris, Q. (2010). The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res 38, W214–W220.
67. KO mice. PLoS ONE 6, e26549.
68. Wu, H., Xu, J., Pang, Z.P., Ge, W., Kim, K.J., Blanchi, B., Chen, C., Sudhof, T.C., and Sun, Y.E. (2007). Integrative genomic and functional analyses reveal neuronal subtype differentiation bias in human embryonic stem cell lines. Proc Natl Acad Sci USA 104, 13821–13826.
69. Zang, J.B., Nosyreva, E.D., Spencer, C.M., Volk, L.J., Musunuru, K., Zhong, R., Stone, E.F., Yuva-Paylor, L.A., Huber, K.M., Paylor, R., Darnell, J.C., Darnell, R.B., and Cox, G.A. (2009). A mouse model of the human fragile X syndrome I304N mutation. PLoS Genet 5, e1000758.
70. Zhang, X.Q., and Zhang, S.C. (2010). Differentiation of neural precursors and dopaminergic neurons from human embryonic stem cells. Methods Mol Biol 584, 355–366.
71. Zheng, S., Chou, A.H., Jimenez, A.L., Khodadadi, O., Son, S., Melega, W.P., and Howard, B.D. (2002). The fetal and neonatal brain protein neuronatin protects PC12 cells against certain types of toxic insult. Dev Brain Res 136, 101–110.